BENEFIX
Biological
PFIZER INC.
Total Payments
$1.3M
Transactions
444
Doctors
170
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $53,501 | 97 | 42 |
| 2023 | $22,884 | 37 | 24 |
| 2022 | $5,400 | 18 | 15 |
| 2021 | $7,134 | 35 | 27 |
| 2020 | $16,165 | 112 | 43 |
| 2019 | $350,559 | 33 | 13 |
| 2018 | $458,646 | 28 | 12 |
| 2017 | $377,456 | 84 | 59 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 105 | 85.8% |
| Consulting Fee | $112,954 | 53 | 8.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $44,255 | 24 | 3.4% |
| Space rental or facility fees (teaching hospital only) | $17,500 | 6 | 1.4% |
| Travel and Lodging | $3,842 | 14 | 0.3% |
| Food and Beverage | $3,759 | 105 | 0.3% |
| Education | $1,597 | 137 | 0.1% |
Payments by Type
Research
$1.1M
105 transactions
General
$183,906
339 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 2016 ASPIRE US HEMO PHARMACOKINETICTAILORED APPROACH TO PROPHYLAXIS IN HEMOPHILIA A PTAP HEMO | PFIZER INC. | $237,655 | 0 |
| 2016 ASPIRE US HEMO HEMOPHILIA UTILIZATION GROUP STUDY VII COSTS AND IMPACT OF DISEASE IN OLDER PERSONS WITH HEMOPHILIA | PFIZER INC. | $200,000 | 0 |
| 2017 ASPIRE US HEMO A REEVALUATION OF FIBRINOLYSIS IN HEMOPHILIA | PFIZER INC. | $180,000 | 0 |
| 2017 ASPIRE HEMOPHILIA AWARDS INSIGHTS INTO THE HEMOSTASIS OF HIGHLY POTENT FACTOR IX VARIANTS | PFIZER INC. | $80,000 | 0 |
| 2015 ASPIRE HEMO THE ROLE OF EXTRAVASCULAR FIX IN PREVENTING BLEEDING COMPLICATIONS IN HEMOPHILIA B | PFIZER INC. | $62,475 | 0 |
| BENEFIX CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $29,670 | 16 |
| NONACOG ALFA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $13,200 | 16 |
| MULTICENTER HEMOPHILIA COSTS AND IMPACT OF DISEASE STUDY HEMOPHILIA UTILIZATION GROUP STUDYPART V | Pfizer Inc. | $7,500 | 0 |
| NONACOG ALFA PF05280602 PF05230907 MOROCTOCOG ALFA MULTI PRODUCT FIDANACOGENE ELAPARVOVEC GIROCTOCOGENE FITELPARVOVEC MARSTACIMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,580 | 7 |
| HEMOPHILIA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,560 | 2 |
Top Doctors Receiving Payments for BENEFIX — Page 7
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Hematology & Oncology | Glendale, AZ | $12.08 | 1 |
| , MD | Hematology & Oncology | Glendale, AZ | $12.08 | 1 |
| , M.D | Pediatric Gastroenterology | Santa Barbara, CA | $11.33 | 1 |
| , D.O | Student in an Organized Health Care Education/Training Program | Charleston, WV | $11.33 | 1 |
| , M.D | Pediatric Hematology-Oncology | Indianapolis, IN | $11.33 | 1 |
| , MD | Obstetrics & Gynecology | Denton, TX | $11.33 | 1 |
| , MD | Hematology | Aiea, HI | $11.33 | 1 |
| , MD | Pediatrics | Louisville, KY | $11.33 | 1 |
| Aziza Sedrak | Pediatric Hematology-Oncology | Brooklyn, NY | $11.33 | 1 |
| , PA | Physician Assistant | Oklahoma City, OK | $11.33 | 1 |
| , MD | Pediatric Hematology-Oncology | Omaha, NE | $11.33 | 1 |
| , M.D | Pediatric Hematology-Oncology | Austin, TX | $11.33 | 1 |
| , CRNP | Nurse Practitioner | Philadelphia, PA | $11.29 | 1 |
| , M.D | Pediatrics | Greenville, NC | $11.24 | 1 |
| , M.D | Hematology & Oncology | Columbus, OH | $11.24 | 1 |
| , M.D | Pediatric Hematology-Oncology | Detroit, MI | $11.24 | 1 |
| , M.D | Internal Medicine | Salt Lake City, UT | $11.12 | 1 |
| , M.D | Pediatric Hematology-Oncology | Bethlehem, PA | $11.11 | 1 |
| , D.O | Medical Oncology | Bethlehem, PA | $11.11 | 1 |
| , MD | Pediatric Hematology-Oncology | Hawthorne, NY | $5.04 | 1 |
| , MD | Hematology & Oncology | Farmington, CT | $1.99 | 1 |
Ad
Manufacturing Companies
- PFIZER INC. $1.3M
- Pfizer Inc. $7,513
- PBG PUERTO RICO LLC $16.05
Product Information
- Type Biological
- Total Payments $1.3M
- Total Doctors 170
- Transactions 444
About BENEFIX
BENEFIX is a biological associated with $1.3M in payments to 170 healthcare providers, recorded across 444 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2017 to 2024. In 2024, $53,501 was paid across 97 transactions to 42 doctors.
The most common payment nature for BENEFIX is "Unspecified" ($1.1M, 85.8% of total).
BENEFIX is associated with 10 research studies, including "2016 ASPIRE US HEMO PHARMACOKINETICTAILORED APPROACH TO PROPHYLAXIS IN HEMOPHILIA A PTAP HEMO" ($237,655).